PMC:7029759 / 892-1105 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"42","span":{"begin":83,"end":98},"obj":"Chemical"}],"attributes":[{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D009841"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"s of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advo"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T23","span":{"begin":5,"end":9},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T22","span":{"begin":58,"end":66},"obj":"GO:0042571"},{"id":"T21","span":{"begin":122,"end":127},"obj":"NCBITaxon:10239"},{"id":"T20","span":{"begin":132,"end":138},"obj":"SO:0001026"}],"text":"s of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advo"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":58,"end":66},"obj":"Body_part"},{"id":"T2","span":{"begin":128,"end":131},"obj":"Body_part"},{"id":"T3","span":{"begin":132,"end":138},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84116"}],"text":"s of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advo"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":5,"end":9},"obj":"Chemical"},{"id":"T2","span":{"begin":83,"end":98},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_7754"}],"text":"s of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advo"}